Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 19, 2024

Ipatasertib Plus Paclitaxel for PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic TNBC

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial
Clin. Cancer Res 2024 Jul 26;[EPub Ahead of Print], RA Dent, SB Kim, M Oliveira, C Barrios, J O'Shaughnessy, SJ Isakoff, S Saji, R Freitas-Junior, M Philco, I Bondarenko, Q Lian, D Bradley, H Hinton, MJ Wongchenko, SJ Reilly, N Turner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading